Helus Pharma said its oral chemically modified psilocybin candidate HLP003 met the key endpoints in a phase 3 study in major depressive disorder, producing a 7.6-point placebo-adjusted reduction on the Montgomery–Åsberg Depression Rating Scale at six weeks. The company is developing the drug as an adjunctive treatment in MDD.

The topline efficacy result was stronger than what Jefferies analysts had expected going into the readout. In a note to investors, Jefferies said expectations had been for a 5- to 6-point MADRS separation at Week 6 and concluded the data were competitive to approved antipsychotics. That does not settle the commercial case on its own, but it shifts the discussion from whether the candidate has a late-stage efficacy signal to whether Helus can support that signal with a manageable safety package and a second confirmatory result.

The Data

The phase 3 trial enrolled 222 patients in the intent-to-treat population. Participants received either a 16 mg dose of HLP003 or placebo on Day 1 and then again three weeks later.

At six weeks, the least squares mean reduction from baseline in MADRS total score was 19.5 points for HLP003 versus 11.9 points for placebo, meeting the study’s primary endpoint. The company also said the trial met its secondary endpoint, showing a 7-point placebo-adjusted reduction at 12 weeks.

Helus also pointed to an early effect. By Day 2, 39.3% of patients treated with HLP003 were in remission compared with 15.5% in the placebo group. That rapid onset is part of the strategic appeal for psychedelic-derived depression medicines, especially in a category where speed of response can matter clinically and commercially.

HLP003 is a deuterated serotonergic agonist, also called deuterated psilocin. Fierce Biotech described deuteration as replacing standard hydrogen atoms in the molecule with deuterium, a heavier form of hydrogen, while aiming to keep the drug’s effects the same and make its behavior more rapid and predictable.

Safety And Readthrough

The safety findings were more mixed than the efficacy headline. Helus reported three treatment-related serious adverse events in the HLP003 arm and none in the placebo arm. Company executives said on an investor call that one of those events was a suicide attempt in a non-responder that occurred 55 days after the second dose. Two patients discontinued the study on Day 2 after treatment.

That leaves a familiar challenge for this drug class. A strong MADRS result can create clear late-stage momentum, but regulators, prescribers and payers still have to decide how much operational complexity and adverse-event risk they are willing to accept in return for the efficacy profile. The sources do not provide a full breakdown of adverse events, so it is not yet possible to judge whether the broader tolerability profile will support routine use beyond the topline figures released Monday.

The Policy And Market Context

The readout lands during a more favorable policy stretch for psychedelic developers. Fierce Biotech said President Donald Trump ordered the FDA to prioritize reviews of psychedelic drugs for the treatment of mental illness. Helus did not receive a voucher under the Trump administration’s April announcement, but a company spokesperson had previously said that the move created momentum for companies like Helus and could support interest in its clinical programs and progress toward regulatory submissions.

The broader field has also become more active. Eli Lilly bought AtaiBeckley for $2.8 billion upfront in July, and Compass Pathways completed its rolling FDA submission today for its psilocybin formulation for depression, according to Fierce Biotech. That means Helus is advancing in a market that may not be educating physicians and regulators from scratch by the time it reaches filing.

A separate phase 3 trial is due to read out in the fourth quarter of 2027. That next study now carries more weight than a routine follow-up: if it confirms this magnitude of effect without amplifying safety concerns, HLP003 could move from a psychedelic-adjacent science story into a more conventional late-stage depression asset with a clearer competitive position.